Skip to main content
Daan Gene Co., Ltd. logo

Daan Gene Co., Ltd. — Investor Relations & Filings

Ticker · 002030 ISIN · CNE000001KP1 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 2,189 across all filing types
Latest filing 2025-08-29 Governance Information
Country CN China
Listing Shenzhen Stock Exchange 002030

About Daan Gene Co., Ltd.

https://www.daangene.com

Daan Gene Co., Ltd. specializes in the development and manufacturing of molecular diagnostic products and services. The company focuses on in vitro diagnostic technologies, particularly polymerase chain reaction (PCR) platforms. Its product portfolio includes diagnostic kits for infectious diseases, genetic screening, and oncology, alongside automated nucleic acid extraction systems and real-time PCR instruments. Daan Gene provides comprehensive solutions for clinical laboratories and public health institutions, integrating research, production, and clinical testing services. The organization emphasizes technological innovation in molecular biology to support precision medicine and disease control.

Recent filings

Filing Released Lang Actions
股东会议事规则（2025年8月）
Governance Information Classification · 100% confidence The document is titled as "股东会议事规则" which translates to "Rules of Procedure for Shareholders' Meetings" of Guangzhou Da An Gene Co., Ltd. It extensively details the procedures, rights, duties, and powers related to shareholders' meetings, including the convening, proposal submission, voting, and resolution processes. It does not contain financial statements, audit opinions, or earnings data. It is a governance document outlining internal rules and procedures for shareholder meetings. Therefore, it fits the category of Governance Information (CGR). The document length is substantial and contains detailed governance rules, not just an announcement or summary, so it is not a Regulatory Filing or Report Publication Announcement.
2025-08-29 Chinese
关于召开2025年第三次临时股东会的公告
Proxy Solicitation & Information Statement Classification · 95% confidence The document is a detailed announcement regarding the convening of the 2025 third extraordinary general meeting of shareholders for Guangzhou Da An Gene Co., Ltd. It includes information about the meeting date, voting procedures (both onsite and online), agenda items, registration details, and proxy authorization forms. There is no financial data, earnings information, or audit content. The document is not a report itself but a notice about the meeting and voting process. It is not a report publication announcement because it is longer than 5,000 characters and contains substantive meeting details rather than just a brief notice. The content fits the definition of a Proxy Solicitation & Information Statement (PSI), as it provides materials sent to shareholders to inform and request votes for the meeting.
2025-08-29 Chinese
半年度非经营性资金占用及其他关联资金往来情况汇总表
Interim / Quarterly Report Classification · 95% confidence The document is a financial summary table detailing non-operating fund occupation and other related party fund transactions for the first half of 2025. It includes specific monetary amounts, accounting subjects, and relationships with related parties. The document is relatively short (2155 characters) and focuses on financial data for a half-year period. It contains substantive financial data and analysis for a period shorter than a full fiscal year, which aligns with the definition of an Interim / Quarterly Report (IR). It is not an announcement or a certification but a detailed financial summary report for the half-year period.
2025-08-29 Chinese
2025年半年度财务报告
Interim / Quarterly Report Classification · 100% confidence The document is titled '2025 年半年度财务报告' which translates to '2025 Semi-Annual Financial Report'. It contains detailed financial statements including consolidated and parent company balance sheets, profit and loss statements, cash flow statements, notes on accounting policies, and other comprehensive financial data. The report explicitly states it is a half-year report for 2025, and it is unaudited. The length of the document is substantial (15,000 characters), and it contains actual financial data and analysis, not just an announcement or certification. Therefore, this document fits the definition of an Interim / Quarterly Report (IR).
2025-08-29 Chinese
关于调整2025年度日常关联交易预计的公告
Regulatory Filings Classification · 95% confidence The document is a detailed announcement regarding the adjustment of the estimated amount of daily related party transactions for the fiscal year 2025 by Guangzhou Da An Gene Co., Ltd. It includes extensive financial data, descriptions of related parties, transaction categories, amounts, and explanations of differences from previous estimates. The document is not a full annual or interim financial report but a specific disclosure about related party transactions, which is a regulatory announcement. It does not contain comprehensive financial statements or management discussion and analysis typical of annual or interim reports. It is also not a simple brief announcement or a certification letter. Therefore, the document fits best under Regulatory Filings (RNS), which is the fallback category for regulatory announcements that do not fit other specific categories.
2025-08-29 Chinese
2025年半年度报告摘要
Interim / Quarterly Report Classification · 100% confidence The document is titled as a "2025 年半年度报告摘要" which translates to "2025 Semi-Annual Report Summary." It contains detailed financial data such as revenue, net profit, cash flow, earnings per share, and asset information for the half-year period. It also includes management discussion on business operations, R&D activities, marketing strategies, and social responsibility efforts. The document explicitly states it is a summary of the half-year report and advises investors to read the full report for comprehensive details. The length of the document is 5453 characters, which is sufficient to contain substantive financial data and analysis. The content matches the characteristics of an Interim / Quarterly Report (IR) as it covers a period shorter than a full fiscal year and includes actual financial statements and management commentary. There is no indication that this is merely an announcement or a certification, so it is not RPA or RNS. Therefore, the correct classification is Interim / Quarterly Report (IR).
2025-08-29 Chinese

Browse filings by year

23 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.